In situ t cells in melanoma

Cancer Immunology Immunotherapy

Volumn 48, Issue 7, 1999, Pages 386-395

  Straten, Per Thor ^a   Becker, Jürgen C ^b   Guldberg, Per ^a   Zeuthen, Jesper ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Anergy; Clonotypic T cells; Immune escape; Senescence; T cell receptor variable regions

Indexed keywords

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CANCER CONTROL; CANCER REGRESSION; CONFERENCE PAPER; HUMAN; IMMUNOMODULATION; IMMUNOSURVEILLANCE; LYMPHOCYTIC INFILTRATION; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE;

ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CELL DIVISION; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPHENOTYPING; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 0000361751     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050591     Document Type: Conference Paper

References (117)

1. Adibzadeh M, Pohla H, Rehbein A, Pawelec G (1995) Longterm culture of monoclonal human T lymphocytes: models for immunosenescence? Mech Ageing Dev 83:171
2. Alberola-Ila J, Takaki S, Kerner JD, Perlmutter RM (1997) Differential signaling by lymphocyte antigen receptors. Annu Rev Immunol 15:125
3. Bachmann MF, McKall-Faienza K, Schmits R, Bouchard D, Beach J, Speiser DE, Mak TW, Ohashi PS (1997) Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 7:549
4. Bakker AB, Phillips JH, Figdor CG, Lanier LL (1998) Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J Immunol 160:5239
5. + human T cell clone by the autologous MHC class II + melanoma. Int Immunol 5:1501
6. Becker JC, Czerny C, Bröcker EB (1994) Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol 6:1605
7. Reference deleted
8. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478
9. Berke G (1997) Killing mechanisms of cytotoxic lymphocytes. Curr Opin Hematol 4:32
10. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279:349
11. Bohm W, Thoma S, Leithauser F, Moller P, Schirmbeck R, Reimann J (1998) T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol 161:897
12. Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP (1999) Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res 59:59
13. Chatterjee-Kishore M, Kishore R, Hicklin DJ, Marincola FM, Ferrone S (1998) Different requirements for signal transducer and activator of transcription lalpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing I gene expression. J Biol Chem 273:16177
14. Chen Q, Daniel V, Maher DW, Hersey P (1994) Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 56:755
15. Chen YZ, Matsushita S, Nishimura Y (1996) Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation. J Immunol 157:3783
16. Clark WH (1991) Tumour progression and the nature of cancer. Br J Cancer 64:631
17. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303
18. Cole DJ, Weil DP, Shamamian P, Rivoltini L, Kawakami Y, Topalian S, Jennings C, Eliyahu S, Rosenberg SA, Nishimura MI (1994) identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res 54:5265
19. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, Rosenberg SA, Marincola FM (1998) Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 75:517
20. Davis MM (1990) T cell receptor gene diversity and selection. Annu Rev Biochem 59:475
21. Dietrich PY, Walker PR, Schnuriger V, Saas P, Perrin G, Guillard M, Gaudin C, Caignard A (1997) TCR analysis reveals significant repertoire selection during in vitro lymphocyte culture. Int Immunol 9:1073
22. Dufour E, Carcelain G, Gaudin C, Flament C, Avril MF, Faure F (1997) Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. J Immunol 158:3787
23. Dustin ML, Ferguson LM, Chan PY, Springer TA, Golan DE (1996) Visualization of CD2 interaction with LFA-3 and determination of the two-dimensional dissociation constant for adhesion receptors in a contact area. J Cell Biol 132:465
24. Effros RB, Pawelec G (1997) Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? Immunol Today 18:450
25. + cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 10:F17-F22
26. Faure F, Even J, Kourilsky P (1998) Tumor-specific immune response: current in vitro analyses may not reflect the in vivo immune status. Crit Rev Immunol 18:77
27. Ferradini L, Roman Roman S, Azocar J, Avril MF, Viel S, Triebel F, Hercend T (1992) Analysis of T-cell receptor alpha/ beta variability in lymphocytes infiltrating a melanoma metastasis. Cancer Res 52:4649
28. Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, Avril MF, Hercend T (1993) Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest 91:1183
29. Ferrick DA, Ohashi PS, Wallace V, Schilham M, Mak TW (1989) Thymic ontogeny and selection of alpha beta and gamma delta T cells. Immunol Today 10:403
30. Ferrone S, Marincola FM (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487
31. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350
32. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363
33. + T cells. World J Surg 19:352
34. Hayflick L (1965) The limited "in vitro" lifetime of human diploid cell strains. Exp Cell Res 37:614
35. Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465
36. Hemmer B, Stefanova I, Vergelli M, Germain RN, Martin R (1998) Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol 160:5807
37. Hemmer B, Vergelli M, Gran B, Ling N, Conlon P, Pinilla C, Houghten R, McFarland HF, Martin R (1998) Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J Immunol 160:3631
38. Hemmer B, Vergelli M, Pinilla C, Houghten R, Martin R (1998) Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol Today 19:163
39. Hicklin DJ, Dellaratta DV, Kishore R, Liang B, Kageshita T, Ferrone S (1997) Beta2-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance. Melanoma Res 7 [Suppl 2]:67
40. Hishii M, Andrews D, Boyle LA, Wong JT, Pandolfi F, van den Elsen PJ, Kurnick JT (1997) In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. Proc Natl Acad Sci U S A 94:1378
41. Kageshita T, Wang Z, Calorini L, Yoshii A, Kimura T, Ono T, Gattoni Celli S, Ferrone S (1993) Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res 53:3349
42. Kawakami Y, Rosenberg SA (1996) T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 15:179
43. Kirkin AF, Dzhandzhugazyan K, Zeuthen J (1998) Melanoma-associated antigens recognized by cytotoxic T lymphocytes. APMIS 106:665
44. Krasagakis K, Garbe C, Schrier PI, Orfanos CE (1994) Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res 14:2565
45. Lanier LL (1998) NK cell receptors. Annu Rev Immunol 16:359
46. Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D (1995) Expression of cytokine mRNA in human melanoma tissue. Cancer Immunol Immunother 41:151
47. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340
48. Letterio JJ, Roberts AB (1998) Regulation of immune responses by TGF-beta. Annu Rev Immunol 16:137
49. Liang P, Averboukh L, Keyomarsi K, Sager R, Pardee AB (1992) Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells. Cancer Res 52:6966
50. Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB (1989) Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244:339
51. (27-35). J Exp Med 184:647
52. + T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Res 58:2433
53. Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM (1997) T helper I cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 108:914
54. Mackensen A, Ferradini L, Carcelain G, Triebel F, Faure F, Viel S, Hercend T (1993) Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res 53:3569
55. Mackensen A, Carcelain G, Viel S, Raynal MC, Michalaki H, Triebel F, Bosq J, Hercend T (1994) Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest 93:1397
56. Madrenas J, Wange RL, Wang JL, Isakov N, Samelson LE, Germain RN (1995) Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science 267:515
57. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ, Lotze MT (1996) Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 98:1633
58. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C, Naeyaert JM, Plangne R, Deraemaeker R, Knuth A, Jäger E, Brasseur F, Herman J, Coulie PG, Boon T (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883
59. Mason D (1998) A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 9:395
60. Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P, Kiessling R (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61:765
61. McLean AR, Michie CA (1995) In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci U S A 92:3707
62. Mingari MC, Moretta A, Moretta L (1998) Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol Today 19:153
63. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, Reali UM, Giannotti B (1997) In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7:313
64. + T cells in patients with multiple myeloma and paraproteinemia. Blood 87:3297
65. - T cell subsets in HIV type 1-infected individuals. Eur J Immunol 28:1738
66. Myers RM, Maniatis T, Lerman LS (1987) Detection and localization of single base changes by denaturing gradient gel electrophoresis. Methods Enzymol 155:501
67. Nagatake M, Takagi Y, Osada H, Uchida K, Mitsudomi T, Saji S, Shimokata K, Takahashi T (1996) Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 56:2718
68. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328
69. Nitta T, Oksenberg JR, Rao NA, Steinman L (1990) Predominant expression of T cell receptor Vα7 in tumor-infiltrating lymphocytes of uveal melanoma. Science 249:672
70. Noppen C, Schaefer C, Zajac P, Schutz A, Kocher T, Kloth J, Heberer M, Colonna M, De Libero G, Spagnoli GC (1998) C-type lectin-like receptors in peptide-specific HLA class I-restricted cytotoxic T lymphocytes: differential expression and modulation of effector functions in clones sharing identical TCR structure and epitope specificity. Eur J Immunol 28:1134
71. Oksenberg JR, Stuart S, Begovich AB, Bell RB, Erlich HA, Steinman L, Bernard CC (1990) Limited heterogeneity of rearranged T-cell receptor Vα transcripts in brains of multiple sclerosis patients. Nature 345:344
72. Olovnikov AM (1996) Telomeres, telomerase, and aging: origin of the theory. Exp Gerontol 31:443
73. Pannetier C, Even J, Kourilsky P (1995) T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today 16:176
74. Pawelec G, Zeuthen J, Kiessling R (1997) Escape from hostantitumor immunity. Crit Rev Oncog 8:111
75. + human haematopoietic stem cells in vitro. Exp Gerontol 34:69
76. Pawelec G, Wagner W, Adibzadeh M, Engel A (1999) T cell immunosenescence in vitro and in vivo. Exp Gerontol (in press)
77. Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P (1994) Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 153:2807
78. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JF, Rosenberg SA (1996) Loss of functional b2-microglobulin in metastatic melanomas from five different patients receiving immunotherapy. J Natl Cancer Inst 88:100
79. Rivoltini L, Loftus DJ, Squarcina P, Castelli C, Rini F, Arienti F, Belli F, Marincola FM, Geisler C, Borsatti A, Appella E, Parmiani G (1998) Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in downregulating anti-tumor T-cell reactivity. Crit Rev Immunol 18:55
80. + CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 161:1220
81. Romero P, Pannetier C, Herman J, Jongeneel CV, Cerottini JC, Coulie PG (1995) Multiple specificities in the repertoire of a melanoma patients cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. J Exp Med 182:1019
82. Rosenberg SA (1988) Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 9:58
83. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907
84. Rosenberg SA, Yang JC, Schwartzentruher DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321
85. Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S (1991) MHC antigens in human melanomas. Semin Cancer Biol 2:35
86. Salvi S, Segalla F, Rao S, Arienti F, Sartori M, Bratina G, Caronni E, Anichini A, Clemente C, Parmiani G, Sensi M (1995) Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res 55:3374
87. - T cells from rheumatoid arthritis patients. J Immunol 161:1018
88. Schmid P, Itin P, Rufli T (1995) In situ analysis of transforming growth factor-betas (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. Carcinogenesis 16:1499
89. - T cells in rheumatoid arthritis. Mol Med 2:608
90. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480
91. Schwarz MA, Hamilton LD, Tardelli L, Narula SK, Sullivan LM (1994) Stimulation of cytolytic activity by interleukin-10. J Immunother 16:95
92. Schøller J, thor Straten P, Birck A, Siim E, Dahlstrom K, Drzewiecki KT, Zeuthen J (1994) Analysis of T cell receptor alpha beta variability in lymphocytes infiltrating melanoma primary tumours and metastatic lesions. Cancer Immunol Immunother 39:239
93. Sensi M, Parmiani G (1995) Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Immunol Today 16:588
94. Sensi M, Castelli C, Salvi S, Mazzocchi A, Mortarini R, Nicolini G, Anichini A, Parmiani G (1992) Expansion of major histocompatibility complex-restricted antimelanoma cytotoxic T-cell lymphocyte clones with identical T-cell receptor from tumor-infiltrating lymphocytes. J Immunother 12:207
95. Shapiro VS, Truitt KE, Imboden JB, Weiss A (1997) CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. Mol Cell Biol 17:4051
96. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H (1998) Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A 95:1178
97. Strohal R, Brna C, Mossbacher U, Fischer G, Pehamberger H, Stingl G (1998) First comparative delineation of the T cell receptor repertoire in primary and multiple subsequent/coexisting metastatic melanoma sites. J Invest Dermatol 111:1085
98. Terheyden P, Siedel C, Merkel A, Kämpgen E, Bröcker EB, Becker JC (1999) Predominant expression of Fas (Apo-1/ CD95) ligand in metastatic melanoma revealed by longitudinal analysis. J Invest Dermatol (in press)
99. Terhorst C, Simpson S, Wang B, She J, Halt C, Huang M, Wileman T, Eichmann K, Hollander G, Levelt C, Exley M (1995) Plasticity of the TCR-CD3 complex. In: Bell JI, Owen MJ, Simpson E (eds) T-cell receptors. Oxford University Press, Oxford, pp 369-395
100. thor Straten P, Schøller J, Hou Jensen K, Zeuthen J (1994) Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. Int J Cancer 56:78
101. thor Straten P, Becker JC, Seremet T, Bröcker EB, Zeuthen J (1996) Clonal T-cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human melanoma. J Clin Invest 98:279
102. thor Straten P, Kirkin AF, Seremet T, Zeuthen J (1997) Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Int J Cancer 70:582
103. thor Straten P, Barfoed A, Seremet T, Säterdal I, Zeuthen J, Guldberg P (1998) Detection and characterization of alpha/ beta clonality by denaturing gradient gel electrophoresis (DGGE). Biotechniqnes 25:244
104. thor Straten P, Guldberg P, Grønbæk K, Zeuthen J, Becker JC (1999) In situ T-cell responses against melanoma comprise high numbers of locally expanded T-cell clonotypes. J Immunol (in press)
105. Reference deleted
106. thor Straten P, Guldberg P, Seremet T, Reisfeld RA, Zeuthen J, Becker JC (1998) Activation of pre-existing T-cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci U S A 95:8785
107. Van Gool SW, Vandenberghe P, de Boer M, Ceuppens JL (1996) CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev 153:47
108. van Oers NS, Love PE, Shores EW, Weiss A (1998) Regulation of TCR signal transduction in murine thymocytes by multiple TCR zeta-chain signaling motifs. J Immunol 160:163
109. Viola A, Lanzavecchia A (1996) T cell activation determined by T cell receptor number and tunable thresholds. Science 273:104
110. Wagner SN, Schultewolter T, Wagner C, Briedigkeit L, Becker JC, Kwasnicka HM, Goos M (1998) Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab Invest 78:541
111. Walker LS, McLeod JD, Boulougouris G, Patel YI, Hall ND, Sansom DM (1998) Down-regulation of CD28 via Fas (CD95): influence of CD28 on T-cell apoptosis. Immunology 94:41
112. Wang Z, Seliger B, Mike N, Momburg F, Knuth A, Ferrone S (1998) Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL- 29.1.22 and SK-MEL-29.1.29. Cancer Res 58:2149
113. Weidmann E, Elder EM, Trucco M, Lotze MT, Whiteside TL (1993) Usage of T-cell receptor Vβ chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. Int J Cancer 54:383
114. - T cells in the aging immune system. Mech Ageing Dev 102:131
115. Wizel B, Palmieri M, Mendoza C, Arana B, Sidney J, Sette A, Tarleton R (1998) Human infection with trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses. J Clin Invest 102:1062
116. Zea AH, Curti BD, Longo DL, Gregory Alvord W, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ, Ochoa AC (1995) Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1:1327
117. Zea AH, Ochoa MT, Ghosh P, Longo DL, Alvord WG, Valderrama L, Falabella R, Harvey LK, Saravia N, Moreno LH, Ochoa AC (1998) Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect Immun 66:499